Observational studyJournal of pregnancy2026
Planned Oocyte Cryopreservation Following the 2021 French Bioethics Law: Women's Characteristics and Early Clinical Outcomes From a Single-Center Observational Study.
Observational study in Journal of pregnancy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPlanned oocyte cryopreservation (POC) has been authorized in France since 2021 within a specific national counselling and reimbursement framework. The primary aim of this study was to describe the sociodemographic characteristics, motivations, and fertility-related knowledge of women seeking POC after implementation of the 2021 French Bioethics Law. Secondary aims were to report early cycle outcomes and explore factors associated with oocyte vitrification outcomes.
methodsWe conducted a descriptive, observational single-center study at Rouen University Hospital, retrospectively analyzing prospectively collected standardized counselling data and POC cycle outcomes. Women registering for POC between September 1, 2021, and December 31, 2022, were included, with follow-up through July 31, 2023. Associations between available clinical and biological parameters and oocyte vitrification outcomes were explored.
resultsOverall, 117 women registered for POC, and 69 attended the POC counselling consultation. Participants had higher educational levels than the general French population; the leading motivations were single status and awareness of age-related decline in ovarian reserve. By July 31, 2023, 40 women had initiated COH treatment and 38 had completed at least one full cycle. The mean number of cryopreserved mature metaphase II oocytes was 12.1 ± 8.8 per woman. Exploratory analyses showed that AMH and AFC were positively associated with oocyte vitrification outcomes, whereas higher BMI was associated with lower oocyte yield and reduced maturation rate.
conclusionIn this early single-center French cohort, women seeking POC were mostly highly educated and were mainly motivated by single status and awareness of age-related fertility decline. Early vitrification outcomes were associated with ovarian reserve markers and BMI. Longer-term follow-up is required to assess oocyte utilization, pregnancy and live birth outcomes, and the impact of publicly funded POC on access to fertility preservation in France.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.